logo

For the Inventor, By the Inventor

Oxford, United Kingdom

Michael C Minchin

This inventor holds 7 USPTO granted patents. Top assignee: John Wyeth Brother, Limited. Active years: 1992-1996.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Michael C Minchin. Retrieved from https://idiyas.com/inventor/michael-c-minchin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7

% Patents Active = 100.0

Average Co-Inventor Count = 2.5

ph-index = 4

Forward Citations = 75(Granted Patents)


Company Filing History:

goldMedal7 out of 299 
 
John Wyeth Brother, Limited
 patents

Years Active: 1992-1996

Loading Chart...
7 patents (USPTO):Explore Patents
1. 5538956 - Amine derivatives containing a phosphonic acid moiety (1996-07-23),
2. 5527955 - Method of treating depression and tri-substituted amines therefor (1996-06-18),
3. 5422355 - Composition for treating depression with (N-heteroaryl)alkylamines (1995-06-06),
4. 5321047 - Method and amines used therein (1994-06-14),
5. 5260331 - Composition for treating depression with (S- or O-heteroaryl)alkyl amines (1993-11-09),
6. 5210088 - Method of treatment and heterocyclic compounds used therein (1993-05-11),
7. 5118690 - Pharmaceutical tetrahydroisoquinolines (1992-06-02),

Title: Michael C Minchin: Innovator in Pharmaceutical Chemistry

Introduction

Michael C Minchin is a distinguished inventor based in Oxford, GB. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for treating mental health conditions. With a total of 7 patents to his name, Minchin's work has garnered attention in both academic and commercial circles.

Latest Patents

Among his latest patents, Minchin has developed innovative methods for treating depression and senile dementia. One notable patent is focused on amine derivatives containing a phosphonic acid moiety. This invention concerns a method for treating depression or senile dementia using a compound that acts selectively as an agonist of gamma aminobutyric acid (GABA) at GABA autoreceptors, with the important proviso that the compound is not fengabine or progabide.

Career Highlights

Minchin is currently associated with John Wyeth & Brother Limited, where he continues to advance his research and development efforts. His work has been instrumental in creating new therapeutic options for patients suffering from mental health disorders.

Collaborations

Throughout his career, Minchin has collaborated with notable colleagues, including John F White and Christine Ennis. These partnerships have facilitated the exchange of ideas and fostered innovation in their respective fields.

Conclusion

Michael C Minchin's contributions to pharmaceutical chemistry and his innovative approaches to treating mental health conditions underscore his importance as an inventor. His ongoing work promises to impact the field significantly, providing new hope for those affected by depression and related disorders.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…